Immunic receives USPTO allowance for vidofludimus calcium patent

Immunic announced that it has received a notice of allowance from the United States Patent and Trademark Office, or USPTO, for patent application 17/391,442, entitled, “Treatment of Multiple Sclerosis Comprising DHODH Inhibitors,” covering a daily dose of about 10 mg to 45 mg of vidofludimus calcium, or IMU-838, and other salt as well as free acid forms for the treatment of relapsing multiple sclerosis, or RMS. The claims are expected to provide protection into 2041, unless extended further.